Publications by the researcher in collaboration with Pedro Antonio Cascales Campos (14)

2026

  1. Corrigendum to “Rectosigmoidectomy versus pelvic peritonectomy in the management of seromuscular involvement of superficial rectal wall tumors in advanced-stage ovarian cancer at complete interval cytoreductive surgery” [Gynecol Oncol. 2026 Apr;207:16-22. doi:10.1016/j.ygyno.2026.02.014. Epub 2026 Feb 25. PMID: 41747472] (Gynecologic Oncology (2026) 207 (16–22), (S0090825826008085), (10.1016/j.ygyno.2026.02.014))

    Gynecologic Oncology

  2. Neoadjuvant Chemotherapy Following Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Retrospective Cohort Study

    Cancers, Vol. 18, Núm. 5

  3. Rectosigmoidectomy versus pelvic peritonectomy in the management of seromuscular involvement of superficial rectal wall tumors in advanced-stage ovarian cancer at complete interval cytoreductive surgery

    Gynecologic Oncology, Vol. 207, pp. 16-22

2025

  1. Challenges of Nontherapeutic Laparotomy in Patients with Peritoneal Surface Malignancies Selected for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

    Cancers, Vol. 17, Núm. 9

  2. Combined Hyperthermic Intraperitoneal Chemotherapy and Normothermic Intraperitoneal Chemotherapy Long-Term After Interval Cytoreduction in Ovarian Cancer: A Phase I Clinical Trial (BICOV1)

    Cancers, Vol. 17, Núm. 12

  3. Peritoneal cancer index in ovarian cancer: what does the surgeon really see?

    Clinical and Translational Oncology, Vol. 27, Núm. 11, pp. 4185-4191

2024

  1. Systematic Cholecystectomy During Cytoreductive Surgery Plus HIPEC: A Critical Analysis of an Empirical Tradition

    Annals of Surgical Oncology, Vol. 31, Núm. 10, pp. 7157-7164

2023

  1. HIPEC in Ovarian Cancer Is the Future… and Always Will Be? Results from a Spanish Multicentric Survey

    Cancers, Vol. 15, Núm. 13

2022

  1. Interval cytoredutive surgery and HIPEC in advanced ovarian cancer with small-bowel disease: results and reflections

    Clinical and Translational Oncology, Vol. 24, Núm. 8, pp. 1542-1548

2021

  1. Acute renal disease in patients with ovarian peritoneal carcinomatosis treated with cytoreduction and HIPEC: the influence of surgery and the cytostatic agent used

    Langenbeck's Archives of Surgery, Vol. 406, Núm. 7, pp. 2449-2456

  2. Urinary and fecal incontinence in patients with advanced ovarian cancer treated with CRS + HIPEC

    Surgical Oncology, Vol. 36, pp. 115-119

2020

  1. Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy

    Clinical and Translational Oncology, Vol. 22, Núm. 6, pp. 852-859

  2. Risk factors and management of incisional hernia after cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal surface malignancies

    Hernia, Vol. 24, Núm. 2, pp. 257-263

2019

  1. Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC

    Clinical and Experimental Metastasis, Vol. 36, Núm. 5, pp. 433-439